All relevant nonGAAP measures are reconciled from their respective GAAP measures in the attached table Reconciliation of GAAP Financial Measures to NonGAAP Financial Measures About EXONDYS 51 EXONDYS 51 uses Sareptas proprietary phosphorodiamidate morpholino oligomer PMO chemistry and exonskipping technology to bind to exon 51 of dystrophin premRNA resulting in skipping of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping